Replimune (REPL) to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs

Go back to Replimune (REPL) to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

April 12, 2021 4:01 PM EDT

Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2

Increased infiltration of CD8+ T cells and PD-L1 expression for patients dosed with RP1 in combination with Opdivo® (nivolumab) and single agent RP2 in human biomarker samplesPre-clinical evidence of innate immune activation mediated by GALV-GP R- expression Gene expression profiling supportive of broad immune activation in both humans & mice Further pre-clinical demonstration of potent lytic activity in tumors

WOBURN, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq:... More